Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

Next Previous
Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nuvisertib (Primary) ; Momelotinib; Ruxolitinib
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology; Tolero Pharmaceuticals

Most Recent Events

  • 08 Dec 2025 According to Sumitomo Pharma Media Release, preliminary safety and efficacy data of nuvisertib monotherapy as well as nuvisertib in combination with momelotinib (MMB) in 18 patients with R/R MF with anemia, collected as of October 15, 2025, were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
  • 08 Dec 2025 Results presented in the Sumitomo Pharma Media Release.
  • 03 Nov 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top